Aims There is no agreement in the best cutoff time to distinguish between early-and late-onset prosthetic valve endocarditis (PVE). Our objectives are to define early-onset PVE according to the microbiological spectrum and to analyse the profile and short-term prognosis of this entity.
Introduction
Despite major advances in cardiovascular surgical techniques and routine use of prophylactic antimicrobial agents, prosthetic valve endocarditis (PVE) continues to complicate the course of a small percentage of patients after cardiac valve replacement. Its incidence is highest within 12 months of valve replacement and ranges between 1.4 and 3.1%. 1, 2 Because distinct features in the clinical course exist when comparing early-and late-onset infections, patients with PVE are usually classified in two groups according to the time elapsed from surgery. There is no agreement regarding the cutoff time to classify a PVE as early or late. Some authors consider 1 year, [3] [4] [5] [6] [7] others 60 days 2, [8] [9] [10] [11] [12] [13] [14] after the surgery, and others distinguish between early-, intermediate-, and late-onset PVE (LO-PVE). 15 , 16 We present a multicentre study with uniform data collection, prospective inclusion of patients, strict definitions of endocarditis, and widespread use of transeophageal echocardiography (TEE) to (i) define the microbiological profile over time to subsequently define the most appropriate cutoff time, (ii) evaluate the clinical, echocardiographic, microbiological, and prognostic profile of early-onset PVE (EO-PVE).
Methods

Patient population
This study was conducted at five tertiary care centres with surgical facilities and involved all consecutive cases of infective endocarditis diagnosed at our centres between 1996 and 2004. To ensure consecutive enrolment, all patients who underwent echocardiography in whom endocarditis was suspected were observed until a diagnosis was established. Patients with a final diagnosis of endocarditis were included in the study. A standardized case report form with 10 epidemiological, 10 clinical, nine analytical, three radiographic, four electrocardiographic, 10 microbiological, and 13 echocardiographic variables was used by all participant centres and all patients were registered on an on-going database.
We have compared the microbiological spectrum according to the time elapsed from surgery (,2 vs. 2-12 months and ,12 vs. .12 months) in order to determine the best cutoff time to distinguish between EO-and LO-PVE. Then, we have described the epidemiological, microbiological, echocardiographic, and evolutive characteristics of EO-PVE and compared the demographic profile of EO-and LO-PVE to determine if there are factors affecting the diferent microbiological characteristics between both entities. Finally, we have analysed the prognostic factors of in-hospital mortality of patients with EO-PVE. Table 1 shows the definitions used throughout the study. Indications for urgent surgery were consesuated by the investigators before the design of the study and included heart failure with prosthetic valve dysfunction, fungal endocarditis, bactereamia or fever after 7 to 10 days of appropriate antibiotic therapy without non-cardiac causes for bacteraemia, and recurrent peripheral embolus despite therapy. All patients underwent transthoracic (TTE) and TEE. The echocardiographic demonstration of a periannular complication was not considered an indication for surgery per se. In-hospital mortality was defined as death occurring during the initial hospitalization for infective endocarditis independently of the aetiology.
Definition of terms and protocol
Statistics
All data for analysis were entered into a computer database SPSS V12.0 (SPSS Inc. Chicago, IL, USA). The Shapiro-Wilk test was used to verify the normality of distribution of continuous variables. The results of normal distributed data were expressed as mean + SD, whereas non-normally distributed data were expressed as median and inter-quartile range. Comparisons were carried out using the Student's t test for normally distributed variables and the MannWhitney U test for non-normally distributed data. Qualitative variables were expressed as count and percentages and compared with x 2 test or Fisher's exact test when necessary. Significance was set at a probability (P) of ,0.05.
Results
Justification of the cutoff time
No differences in the microbiological profile of patients with PVE occurred within 2 months of valve replacement and those accounting between 2 and 12 months were seen ( Figure 1A) . Nonetheless, the microbiological profiles of PVE during and after 1 year were clearly different ( Figure 1B) . The proportion of coagulase-negative Staphylococci (CNS) was higher during the first year post-intervention (37 vs. 18%, P ¼ 0.005); on the other hand, S. viridans were more common causes of PVE after 1 year (18 vs. 1%, P ¼ 0.001). Furthermore the percentage of methicilin-resistant CNS strains was higher in PVE before 1 year (77 vs. 30%, P ¼ 0.004).
Clinical characteristics
A total of 640 episodes of endocarditis according to the Duke criteria 17 were registered in non-drug users between 1996 and 2004, and 172 were prosthetic: 66 (63 definite and three possible) had been acquired in the first year postimplantation and were left-sided (38%). The mean interval between the valve operation and the onset of signs and symptoms of endocarditis was 129 days (range 4-328 days).
Mean age was 59 years (range 28-82 years) and the malefemale ratio was 1:1. The percentage of patients older than 70 years was 21%. The acquisition was nosocomial in 41 cases (62%), previous endocarditis had occurred in 11 (17%), and 18 were referred from other centres (27%). A pre-existing underlying condition was present in 24 patients (36%) ( Table 2) . Fever was the most frequent initial symptom (48 patients, 73%). During admission, 33 patients had dyspnoea, three skin manifestations, and seven splenomegally. During the course of the disease, 35 patients (53%) developed heart failure (11 class III and 10 class IV NYHA), 26 renal insufficiency (39%), 13 stroke (20%), (nine ischaemic and four haemorrhagic), 17 systemic embolism (26%), and seven septic shock (11%).
The chest radiograph showed heart enlargement in 48 patients (73%), pulmonary congestion in 25 (38%), and pleural effusion in 20 (30%). An atrioventricular block was detected in 11 cases (17%).
Microbiological findings
Blood cultures were positive in 55 patients (83%). None of the remaining 11 had positive results in the serology against Clamydia, Mycoplasma, and Legionella and six had been under antibiotic treatment before blood samples were obtained. CNS and S. aureus were the most frequent isolated microorganisms. The majority of CNS (77%) were methicilin resistant. The complete distribution of causative microorganisms is shown in Table 3 .
Echocardiographic findings
Endocarditis affected mechanical prosthesis in mitral position in 33 patients (47%), 29 aortic mechanical prosthesis (41%), five aortic bioprosthesis (7%), and three mitral bioprosthesis (4%). In four cases, two prosthetic valves were affected. TEE revealed valvular vegetations in 53 patients (82%) (mean diameter 12.9 Â 7.4 + 5.8 Â 4.5 mm; mean area 0.75 + 0.63 cm 2 ) and periannular complications in 26 patients (39%): 19 abscesses, 11 pseudoaneurysm, and five fistula (nine patients had more than one periannular complication). Periannular complications were localized in aortic position more frequently than in mitral position but the difference was not statistically significant (52 vs. 31%, P ¼ 0.083).
Treatment and outcome
Urgent surgery was needed on 13 patients (eight with heart failure class III/IV, four with uncontrolled infection, and one for recurrent embolic events), elective surgery was performed in 24 patients, and the remaining 29 patients received only medical treatment. Mortality rates associated with each option are shown on Figure 2 . Among patients treated medically, seven were judged not to be surgical candidates or too ill to undergo an open-heart operation. Overall, mortality was 38% (25 patients), 32% in the surgical group, and 45% in the non-surgical group (P ¼ 0.30). Multiorgan failure with severe sepsis was the most frequent cause of mortality (10 patients). Other causes of mortality were heart failure (n ¼ 7), stroke (n ¼ 3), arrhythmias (n ¼ 2), and perioperative complications (n ¼ 3).
The most frequent type of intervention was the replacement of the infected prosthesis with a mechanical prosthesis (31 patients), followed by the implantation of a homograft (four patients) and a bioprosthesis (two patients).
Comparison between the demographic profile of EO-and LO-PVE
In order to determine if there are patient factors of influence on the microbiological profile of PVE, we have compared the demographic profile of both types of PVE. Results are shown in Table 4 .
Predictors of mortality
A total of 59 epidemiological, analytical, clinical, microbiological, and echocardiographic variables were analysed to find out whether mortality could be predicted. The univariate results of the most clinically meaningful variables are shown in Table 5 . Remarkably, laboratory findings and microbiological profile did not predict mortality in the univariate analysis.
Discussion
PVE is a quite infrequent disease but has a great impact given the high morbidity and mortality which it bears. It accounts for 27% of all cases of infective endocarditis treated in our centres, a similar proportion to that presented by other groups. 8 Optimal management of patients with infected prosthetic cardiac valves represents a challenge for both physicians and surgeons. The most appropriate treatment approach of PVE, either medical or surgical, is still a matter of debate because no randomized, controlled studies had been undertaken. ACC/AHA 18 and the European guidelines 19 advocate surgery for EO-PVE (indication class I) but reviewing most series in the literature, the degree of fulfillment of this indication is low. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Ours and other investigators 3, 7, 11, 13, 20 show that there is no clear evidence that all patients with EO-PVE should be treated surgically on a systematic basis, because there are patients with good prognosis who can undergo medical treatment alone. We do believe that this decision must be individualized and many factors have to be taken into account. PVE have been classically classified into two groups (EO-and LO-PVE) according to the time elapsed from the valve substitution to the onset of symptoms. There is no agreement in the cutoff time and it is often arbitrarily established. Conceptually, EO-PVE are acquired in the perioperative period (in the operatory room or in the immediate post-operative period throughout the infection of incisions, central catheters, urinary probes, etc). LO-PVE are acquired in the community and the microbiological profile mirrors of native valve endocarditis. Therefore, the difference between EO-and LO-PVE should be based on microbiological aspects rather than on the time elapsed from surgery. According to differences in the microbiological profile, we have found the cutoff time of 1 year after operation to be the most appropriate. Moreover, the only difference in the demographic profile of EO-and LO-PVE was that nosocomial acquisition was more frequent between EO-PVE. The microorganisms responsible for EO-PVE in our study were similar to previous reported series. [3] [4] [5] 9, 14, 21 The pathogen profile of EO-PVE is dominated by Staphylococcal species (coagulase-negative and S. aureus) accounting for 37 and 24% of cases, respectively, even though prophylactic regimens used today in cardiac surgery are targeted against these microorganisms.
22,23 Interestingly, the majority of infections caused by CNS were resistant to methicilin (77%), which is a strong argument suggesting the nosocomial origin of many PVE occurring during the first year after valve replacement.
Studies addressing the outcome of PVE have been retrospective, 4, 5, 9 come from a single institution, 4 and consider different times for outcome assessment. Our work is unique in several ways: (i) it is a multicentre study; (ii) our patients were consecutively and prospectively included; (iii) all patients underwent TEE; (iv) a uniform data collection and diagnostic and therapeutic criteria have been used from the beginning of the study; (v) a large number of variables has been analysed; and (vi) strict definitions of endocarditis and complications have been used. Periannular complications were very common in our population, with a proportion similar to that described in previous studies. 16 TEE is clearly better than TTE in the diagnosis of periannular complications with sensitivity and specificity rates of 87 and 95% for TEE, which compares favourably with 28 and 99% for TTE. 24 One of the most relevant findings of our work is that periannular complications were the only factor associated with higher in-hospital mortality rates in our patients. They have been already identified as predictors for surgical recurrence 12 and worse long-term prognosis, 25, 26 but this is the first study to report periannular complications as predictors for in-hospital mortality in patients with EO-PVE. Keeping these considerations in mind, it seems wise to perform TEE on every patient with EO-PVE. Our rate of complications, surgery, and in-hospital mortality rates are similar to that reported by other authors 3, 6, 8, 10 and lower than described in classical text books, 27, 28 which could be explained by the advance in the diagnosis, detection, and earlier treatment of complications of the disease experimented in the last decades.
The low use of homografts in our series (only 11%) is explained by the unavailability to obtain them on an urgent basis. In fact, homographs were not used in any patient who required urgent surgery. Regarding the low use of bioprosthesis, we followed the same criteria irrespective of whether the patient has endocarditis or non-infectious valvular disease. Only three of patients were older than 70 and a bioprosthesis was implanted in two of them.
We are aware of potential weaknesses of the present study. First, this is an observational study and allocation of therapies was not randomized. Thus, bias in the selection of therapies was present. Second, ours are large reference centres that obviously introduce a bias in the patients included in our database. Thus, our conclusions are pertinent to tertiary care centres with surgical facilities and cannot be generalized. Nevertheless, it has to be agreed that every patient with EO-PVE should be treated in a hospital of this nature. Finally, another drawback is the limited number of patients included which make our conclusions not definite; to our knowledge, however, it is one of the largest recent series published in the literature and our results may contribute in the better understanding of this devastating disease.
